FDA Busts Johnson & Johnson and Sientra Over Breast Implant Safety
The U.S. Food and Drug Administration recently issued warning letters to two major manufacturers of breast implants for failure to meet the agency’s post-approval study requirements.
In its letters, the FDA alleges that J&J and Sientra failed to comply with the agency’s requirements for further scientific study after the implants were originally approved to sell on the market.
The warning letters come on the heels of an FDA warning last month that a breast implants could be related to a particular type of lymphoma. Now, the agency is shining a light on problems with the companies’ post-approval studies that were mandated by the agency. These studies included evaluating breast implants’ long-term safety.
In its letter to J&J, the FDA highlighted several serious problems with the company’s post-approval study, particularly for its breast implant brand MemoryShape, which was approved by the FDA in 2013. The FDA cited deficiencies, including J&J’s poor patient accounting, its failure to enroll the required number of patients in the study, missing data on patient race and ethnicity, and other data inconsistencies.
J&J’s aesthetics unit, Mentor Worldwide LLC, said that it was disappointed to receive the FDA’s letter, particularly when it was in the process of trying to resolve post-approval study issues with the agency. A spokesperson for Mentor said that it had made multiple attempts to discuss the study issues with the FDA, but that the agency had failed to provide feedback.
Similarly, Sientra was also cited in the FDA’s letter as having deficiencies in its post-approval research study. Specifically, the FDA highlighted that Sientra’s patient follow-up rate of 61% was poor and was inadequate to evaluate the long-term safety of its implants. The company was under mandate from the FDA to evaluate its study subjects each year for a total of ten years.
In response to the letters, the FDA is asking both companies to provide written responses within 15 business days that illustrate how each company’s violations will be corrected. If J&J and Sientra don’t fix the mistakes, though, the agency may revoke the premarket approval for their products.
The safety of breast implants, particularly for long-term use, has been studied and questioned frequently over the years. They are widely used in the U.S. and abroad for aesthetic procedures such as voluntary breast augmentation as well as reconstruction procedures.
But the use of breast implants has been debated between manufacturers, the FDA, and patient advocacy groups for decades. Breast implants have been the reason for numerous complaints, patient health problems and lawsuits. In response to these problems, the FDA imposed a moratorium on breast implants, banning them from the US market from 1992 to 2006. When that ban was lifted in 2006, the FDA required every manufacturer of breast implants to conduct at least six post-approval studies. These studies are intended to assess the effectiveness and safety of each company’s breast implant product, as well as address specific scientific questions about the products’ long-term safety in patients.
The FDA said that its post-approval requirements are critical to ensure the safety of medical products like breast implants, as well as their effectiveness. The agency intends to hold manufactures
accountable for meeting the study requirements and says will continue to do so until the agency’s post-approval obligations are met.
Hospitals Determining Repair or Replace for Faulty Infusion Pumps
Becton Dickinson, a manufacturer of infusion pumps, recently issued a recall for the Alaris infusion pump. This issue has left hospitals trying to determine if they should have the product repaired or replaced.
An infusion pump has the task of delivering medications intravenously, including pain meds and antibiotics. The pump also delivers blood to patients who need it. The device is used on patients of all ages, from infants to adults.
Dangers of Infusion Pump Malfunction
When an infusion pump malfunctions, it can deliver the medication too fast or not fast enough. If the medication is delivered too slowly, it may be ineffective at treating the condition. However, when medication is delivered too quickly, it can be fatal.
Hospitals must decide if they will repair the pumps by replacing as many as 7000 components on the device. The other option is to monitor the pump for defects. Many facilities are choosing to monitor the pumps since they haven’t had an issue with malfunctioning. Trinity Health is replacing the pumps at its hospitals around the country. Munson Healthcare is replacing half of the pumps but hasn’t decided on a product. Becton Dickinson products make up around 80 percent of the market for infusion pumps.
Other products do exist, including pumps from Johnson & Johnson, Coviden, Baxter, ICU Medical, B Braun and Hospira. The pumps range in size and can cost between $1000 and $3000 with some products even higher in price.
The FDA labelled several recalls as Class 1, which means that the device could cause death or serious injury. Another recall received the label of Class 2, which may still cause harm to a person but the damage is temporary or can be reversed through medical means. Becton Dickinson responded by issuing voluntary recalls in February of 2020. At that time, over 1100 incidents had been reported with 55 injuries and one fatality. The recall affects multiple products in different series.
Products included in the recall date back to 2004 through 2019 to a total of 774,000 units that have been sold in the US. These devices may interrupt infusion, delay it, or have faster or slower delivery. Becton Dickinson has admitted that 13 models of the infusion pumps have had various problems with either the software or hardware. However, the manufacturer says the devices don’t necessarily need to be replaced or stop being used. Critics say that all the pump models included in the Class 1 recalls should be removed and destroyed.
The manufacturer’s instructions to hospitals gave the facilities the option to either removed and discard the pumps or to have them updated with new software and training for nurses. Some medical staff say they haven’t been taught how to use the devices with the new guidelines. Others say they have been given the information for monitoring these devices.
Hospital administration bear the burden of deciding how to respond to the recall to protect patients and manage the budget. Medical staff can only follow the requirements of their facilities and the guidelines of the manufacturer.
New Approved Treatment Becomes Available for Mesothelioma
A new treatment for patients diagnosed with mesothelioma has recently been approved by the FDA and is now available at the West Cancer Center in Memphis, TN. This is the first center in the nation to use electric therapy treatment for these patients.
An Exciting New Treatment
Electric therapy treatment works by sending electric fields into the body to target cancerous cells. The technician applies three pads to the front and back of the patient. Once the unit is turned on, electric fields are sent through the person’s body to disrupt the growth of the cancerous cells. At the same time, it leaves the healthy cells alone.
The new treatment promises to be popular because it’s not invasive. There are few side effects as well. The first patient has received the treatment, and they are wearing it for 18 hours each day. It is expected to have 97 percent control in the first year. If the patient uses the treatment along with chemotherapy, they may have a stable disease or positive response.
The device was first introduced in 2015 to treat brain tumors. It has since been used with ovarian and pancreatic cancer. It’s not being labeled as a cure, but it does help patients live longer. People diagnosed with mesothelioma normally have about two years life expectancy because this is an aggressive cancer. It’s rare, which makes research and treatment difficult.
Before the new treatment was approved, there were three options for treating mesothelioma, which included surgery, chemotherapy and radiation.
What is Mesothelioma?
Mesothelium is the tissue in the lining of your lungs, heart, stomach and other organs. Mesothelioma is a cancer of that tissue. It generally starts in the lungs, but it can begin in other organs as well. This condition has been linked to exposure to asbestos because the asbestos fibers get in the lungs when inhaled where they can’t disappear. Over time with constant exposure, more fibers get into the lungs. Symptoms of this disease often wait 20 or 30 years after exposure to show up. It starts with shortness of breath or pain in the chest. Fluid begins to accumulate, making it even more difficult to breathe.
Anyone who has been exposed to asbestos is at greater risk for developing mesothelioma. Even if you live with someone who works in the industry around asbestos can have an increased risk because they can inhale the fibers from that person’s clothing.
This type of cancer usually isn’t diagnosed until it’s advanced. The doctor will often order an X-ray of the chest or CT scan. If abnormalities are found, a biopsy may be ordered. After it has been analyzed, the results will tell if it is cancerous. Diagnosis could happen much more quickly if the person knows they were exposed to asbestos, but many people don’t think about these details of a job from 20 or 30 years ago.
Mesothelioma patients may find new hope with the treatment if it enhances the quality and quantity of their lives.
Hernia Mesh Defective Products Cause Lifelong Complications
Hernia mesh products have been around since the 1950s when they were first developed. They have become widely accepted as a method to repair hernias. Over time, manufacturers have altered these products with new materials, various coatings and unique features. Some of the mesh products have been proven to be defective, even to the point of causing life-changing injuries.
Multiple Defective Products
Even though hernia mesh products have been around for decades, new products are continually being introduced and not all of them are safe. Some of these products contain different materials and have not been tested thoroughly to determine safety. Often, additional surgery is required to remove the mesh and to repair the hernia again that the first mesh failed to treat.
Some of the products involved in lawsuits include the following:
- Covidien – one of the most recognizable names, Covidien has had numerous claims against its products. Parietex hernia mesh was one product that used the material polyester rather than polypropylene. While it tried to fix the problems associated with this product, it did not test the safety of the mesh before putting it on the market.
- Bard – another well-known name, Bard has a product called Sepramesh IP Composite, which is supposed to incorporate itself into the tissue and is made with polyglycolic acid and polypropylene. It is used in reconstructing soft tissue loss, but has been associated with serious side effects, including bowel obstruction and adhesions, which often require surgeries to correct.
- Ethicon – the Ethicon Physiomesh was approved by the Food and Drug Administration (FDA) in April 2010 and launched as a product in October 2010. However, it was taken off the market voluntarily because of issues with the base layer, which is made of polypropylene. This plastic material is coated with polymeric films which is supposed to cause the material to degrade, but it often remains in the person’s body for a long time.
- Atrium – The Atrium C-QUR was approved for use by the FDA in March 2006, but it has been associated with problems. Two versions, one used for pre-peritoneal repairs and another with placement in the intra-abdominal area, were designed for small hernia issues.
Complications from Hernia Mesh Products
Hernia mesh products can cause a wide range of side effects. The most minor include severe pain, but most require surgery to fix the problem. The most common complications from this product is also the most serious. Adhesion and bowel obstruction are common along with the risk of rejection, migration and infection.
One of the most common complications is adhesion which causes scar-like tissue to stick together and results in chronic pain that may be severe. It can lead to bowel obstruction which can be life-threatening.
In one case, a hernia mesh product attached to the small intestine of a patient. It was necessary to remove the mesh just 12 days after the original surgery to implant it. The mesh products are usually coated to prevent the risk of adhesion, but the coating is dissolved in the body in a short time, which then allows the product to adhere to the intestines or other tissue.
The mesh can also migrate to other areas of the body, where it can cause other issues. One of the most severe and dangerous complications is bowel obstruction. The person begins to feel nauseated and vomits and is unable to pass stool or even gas. Treatment is necessary immediately or the person can die. The obstruction will cut off blood flow if not treated quickly, which will allow part of the intestine to die and need to be removed. According to the FDA, a major reason for bowel obstruction is due to recalled mesh.
Bowel perforation is another serious condition which happens from hernia mesh. It occurs when the product punctures the bowel. The mesh can also perforate other organs or the abdominal wall. Symptoms include nausea and vomiting, severe pain in the abdomen and rigidity. Bacteria gets into the abdominal cavity and leads to peritonitis or sepsis and requires immediate medical attention.
These and other complications may occur right away after the initial surgery. However, it can also be years before a person experiences the complications. With the longer wait, it can take some time to realize the direct cause is the hernia mesh. Lawsuits have been filed for hernia mesh complications that resulted from recalled products or those that have been deemed to be defective. The cost of repair can be quite a financial burden with multiple surgeries and even permanent damage.
Defective Products3 years ago
Dehumidifier Recall: Several Brand Name Humidifiers are Recalled as a Fire Hazard
Medical Devices4 years ago
Complications from Hernia Mesh
Covid-193 years ago
Metformin as Potential Protector from COVID-19
Covid-192 years ago
Moderna Seeks Emergency Approval for COVID Vaccine
Prescription Drugs2 years ago
Recall for Drug Mix-up with Serious Effects
Prescription Drugs3 years ago
Some Heart Meds May Come with Extra Risk
Covid-193 years ago
FDA Adds Nearly Two Dozen Drugs to Watch List
Prescription Drugs2 years ago
Senate Bill May Give More Authority to the FDA for Drug Recall